Molecular Imaging Market Report: Market Size & Forecast 2026

Molecular imaging enables clinicians to detect diseases at the cellular level before anatomical changes become apparent, making it a critical tool in oncology, cardiology, and neurology. The market encompasses imaging equipment, radiopharmaceuticals, contrast agents, and associated software and services. North America holds the largest regional share, supported by advanced healthcare infrastructure and high diagnostic imaging utilization rates.

• •Primary modalities include PET, SPECT, MRI, and CT, with PET and SPECT dominating functional imaging applications
• •Oncology represents the largest application segment, accounting for the majority of molecular imaging procedures
• •The market spans equipment manufacturing, radiopharmaceutical supply, software development, and imaging service providers

The aging global population is a primary catalyst, as older demographics exhibit higher incidence rates of cancer, cardiovascular disease, and neurodegenerative conditions requiring advanced diagnostic imaging. Technological innovation, including the development of new radiopharmaceuticals, AI-assisted image analysis, and hybrid systems like PET/MRI, is expanding clinical utility and procedural accuracy. Rising healthcare spending in developing nations and growing awareness of early disease detection benefits are also fueling demand.

• •Increasing cancer prevalence worldwide drives demand for PET and SPECT imaging in diagnosis, staging, and treatment monitoring
• •Technological advances in radiopharmaceuticals, including theranostics combining therapy and diagnostics, create new revenue streams
• •Expanding healthcare access in Asia-Pacific, Latin America, and the Middle East opens significant new market opportunities

By modality, PET scanners represent a substantial and growing segment, particularly for oncology applications, while SPECT remains important for cardiac imaging. MRI holds a strong position in neurological applications. Geographically, North America leads in market share, while Asia-Pacific is anticipated as the fastest-growing region, propelled by medical tourism, rising incomes, and healthcare infrastructure investments in China, India, and Southeast Asian nations.

• •Oncology is the dominant end-use segment, followed by cardiology and neurology, with emerging applications in infection and inflammation imaging
• •Asia-Pacific is expected to register the highest growth rate, supported by government healthcare investments and expanding hospital networks
• •The United States molecular imaging market is projected to expand at a CAGR around 4%, reflecting steady demand from established healthcare systems

What are the recent trends and outlook?

The convergence of artificial intelligence with molecular imaging is expected to enhance image interpretation speed and accuracy, potentially reducing operational costs and improving diagnostic outcomes. Personalized medicine approaches leveraging molecular imaging for patient stratification and treatment selection are gaining clinical momentum. The market is forecast to reach between $11 billion and $14 billion by 2030-2035, depending on the source, reflecting sustained long-term demand, though challenges around radiopharmaceutical supply chain constraints and equipment costs may moderate growth in certain segments.

• •AI integration for automated lesion detection, quantitative imaging biomarkers, and workflow optimization is becoming a key competitive differentiator
• •Theranostic approaches, particularly in nuclear medicine using targeted radiopharmaceuticals, represent an emerging high-value segment combining diagnosis and therapy
• •Market projections to 2030-2035 range from $11.4 billion to $14.2 billion, with consensus growth rates between 4.5% and 6% CAGR depending on methodology and geographic scope